Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Over an 11-year period, 164 patients with genital tract carcinoma were managed at the Austin Hospital, Melbourne. For patients receiving primary treatment at the hospital, the five-year survival rates of patients with carcinoma of the cervix, endometrium, and ovary were 47.8%, 41.6% and 4.3% respectively. Improved results rest upon earlier diagnosis and alternative therapeutic measures, especially for carcinoma of the endometrium and ovary. Routine surveillance after initial therapy may detect asymptomatic metastatic disease when curative treatment is still possible.
 ...
PMID:Carcinoma of the cervix, endometrium, and ovary: an 11-year review. 47 Jul 24

The objectives of the study were to assess the relationship between the serum levels of MMP-9 and NGAL and the clinical staging and histopathological grade of the tumor. Lipocalin-2/NGAL and MMP-9 concentrations were quantified in serum by multiplex fluorescent bead-based immunoassays (Luminex Corporation, Austin, TX, USA). The AUC values for NGAL and MMP-9 were 0.9 and 0.78, respectively. The diagnostic potential of NGAL and MMP-9 in differentiating high-stage (FIGO III and IV) and low-stage (FIGO I and II) cancer and predicting the cell differentiation grade (G1 versus G3) on the basis of the analyses of AUC values was determined to be 0.91 and 0.79 for NGAL and 0.82 and 0.84 for MMP-9, respectively. Multifactorial logistic regression analysis in the final method revealed that NGAL and MMP-9 variables were independent of the endometrial cancer risk. OR values for NGAL and MMP-9 were 1.23 (95% CI 1.421-3.27; p = 0.034) and 1.09 (95% CI: 1.38-4.12; p = 0.026), respectively. The NGAL/MMP-9 complex may be useful in the assessment of tumor stage before surgical treatment.
 ...
PMID:Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer. 2908 66